-
Detailed Analysis Generate Full Report Add to Watchlist
Values as of: 2025-05-13
IVBIY:OTC-IVBIY (USD)
COMMON STOCK | Biotechnology |
Last Closing
USD 26.11Change
0.00 (0.00)%Market Cap
USD 11.04BVolume
N/AAnalyst Target
N/AVerdict
Verdict
Values as of: 2025-05-13
COMMON STOCK | Biotechnology |
Last Closing
USD 26.11Change
0.00 (0.00)%Market Cap
USD 11.04BVolume
N/AAnalyst Target
N/AVerdict
Verdict
Innovent Biologics, Inc., a biopharmaceutical company, develops, manufactures and commercializes monoclonal antibodies and other drug assets in the fields of oncology, ophthalmology, autoimmune, and cardiovascular and metabolic diseases in China. It offers Tyvyt, a human anti-PD-1 monoclonal antibody; BYVASDA, a fully human anti-VEGF monoclonal antibody; HALPRYZA, a recombinant chimeric murine/human anti-CD20 monoclonal antibody; SULINNO, a fully human antiTNF-a monoclonal antibody; Pemazyre, a selective FGFR inhibitor; Olverembatinib, a novel BCR-ABL TK; Cyramza, a VEGF receptor 2 antagonist; and Retevmo, a selective and potent RET kinase inhibitor. The company is also developing Fucaso, a fully human (BCMA)-directed CAR-T cell; Dupert, a novel KRAS G12C inhibitor; DOVBLERON, a novel next-generation ROS1 TKI in-licensed ; Jaypirca, a non-covalent (reversible) BTK inhibitor; SYCUME, a recombinant IGF-1R monoclonal antibody; IBI354, a recombinant anti-HER2 ADC; IBI389, a first-in-class CLDN18.2/CD3 bispecific T cell engager; IBI3009,a potential best-in-class DLL3-targeting ADC; IBI3001, a potentially bispecific ADC against B7-H3 and EGFR; IBI3020,potential dual payload ADC targeting CEACAM5; IBI356,a potential anti-OX40L monoclonal antibody; IBI355,a potential anti-CD40L monoclonal antibody; IBI3002, a first-in-class TSLP/IL-4a bispecific antibod; IBI3016,a siRNA drug candidate targeting AGT; collaborated with SanegeneBio;and IBI112, a novel long-acting anti-IL-23. In addition, it develops IBI110, a novel anti-LAG3 monoclonal antibody; IBI939, a novel anti-TIGIT monoclonal antibody; IBI310, an anti-CTLA4 monoclonal antibody; IBI323, a novel LAG3/PDL1 bispecific antibody; IBI-363, a potential PD-1/IL2 bispecific antibody fusion protein; IBI-343, a recombinant anti-CLDN18.2 monoclonal ADC; and IBI302, a potential anti-VEGF/complement bispecific fusion protein. Further, the company develops IBI128, a late-stage novel non-purine xanthine oxidase inhibitor; and IBI311, a recombinant anti-IGF-1R monoclonal antibody. Add
Company Website : https://www.innoventbio.com
Currency: USD
Country : USA
Symbol | Name | Price(Change) | Market Cap |
---|---|---|---|
ARGNF | argenx SE |
N/A |
USD 42.54B |
UCBJY | UCB SA ADR |
-0.78 (-0.88%) |
USD 33.33B |
UCBJF | UCB SA |
N/A |
USD 33.01B |
GNMSF | Genmab A/S |
-7.40 (-3.77%) |
USD 12.01B |
WXXWY | WuXi Biologics (Cayman) Inc |
-0.06 (-1.01%) |
USD 10.47B |
WXIBF | WuXi Biologics |
N/A |
USD 10.43B |
AKESF | Akeso, Inc. |
+0.24 (+2.27%) |
USD 9.51B |
SBMFF | Sino Biopharmaceutical Limited |
N/A |
USD 9.09B |
SBHMY | Sino Biopharmaceutical Ltd ADR |
N/A |
USD 9.09B |
TLPPF | Telix Pharmaceuticals Limited |
+0.86 (+5.50%) |
USD 5.56B |
N/A
Market Performance vs. Industry/Classification (Biotechnology) | Market Performance vs. Exchange | ||||||
Value | Sector Median | Percentile Rank | Grade | Market Median | Percentile Rank | Grade | |
YTD | |||||||
Capital Gain | 36.34% | 80% | B- | 81% | B- | ||
Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
Total Return | 36.34% | 80% | B- | 81% | B- | ||
Trailing 12 Months | |||||||
Capital Gain | N/A | N/A | N/A | N/A | N/A | ||
Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
Total Return | N/A | N/A | N/A | N/A | N/A | ||
Trailing 5 Years | |||||||
Capital Gain | N/A | N/A | N/A | N/A | N/A | ||
Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
Total Return | N/A | N/A | N/A | N/A | N/A | ||
Average Annual (5 Year Horizon) | |||||||
Capital Gain | N/A | N/A | N/A | N/A | N/A | ||
Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
Total Return | N/A | N/A | N/A | N/A | N/A | ||
Risk Return Profile | |||||||
Volatility (Standard Deviation) | N/A | N/A | N/A | N/A | N/A | ||
Risk Adjusted Return | N/A | N/A | N/A | N/A | N/A | ||
Market Capitalization | 11.04B | 98% | N/A | 91% | A- |
Target Price Action | Rating Action | Analyst | Rating | Price | Date |
---|
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
The company had positive total cash flow in the most recent four quarters.
The company had positive total free cash flow in the most recent four quarters.
This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
The stock is trading high compared to its peers median on a price to book value basis.
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
This stock has shown below median earnings growth in the previous 5 years compared to its sector